Guardant Health struck a partnership with Zephyr AI to combine Guardant’s multimodal molecular data from its oncology test platform with Zephyr’s analytics to accelerate discovery of genomic biomarkers for drug development and therapy selection. The collaboration will integrate with Guardant’s Infinity AI suite to improve predictions of targeted therapy response and therapy monitoring. Guardant emphasized that coupling large, clinical‑grade molecular datasets with advanced analytics will help sponsors de‑risk trials and refine companion diagnostics. Financial terms were not disclosed; Guardant called the tie‑up a step toward precision oncology applications for biopharma partners. The deal reflects broader industry momentum to combine clinical sequencing data and machine learning for actionable biomarker generation and trial enrichment.